Digoxin immune fab: Difference between revisions
| Line 19: | Line 19: | ||
''' [[Digoxin Immune Fab indications and usage|Indications and Usage]]''' | ''' [[Digoxin Immune Fab indications and usage|Indications and Usage]]''' | ||
'''| [[Digoxin Immune Fab dosage and administration|Dosage and Administration]]''' | '''| [[Digoxin Immune Fab dosage and administration|Dosage and Administration]]''' | ||
'''| [[Digoxin Immune Fab contraindications|Contraindications]]''' | '''| [[Digoxin Immune Fab contraindications|Contraindications]]''' | ||
'''| [[Digoxin Immune Fab adverse reactions|Adverse Reactions]]''' | '''| [[Digoxin Immune Fab adverse reactions|Adverse Reactions]]''' | ||
'''| [[Digoxin Immune Fab drug interactions|Drug Interactions]]''' | '''| [[Digoxin Immune Fab drug interactions|Drug Interactions]]''' | ||
| Line 29: | Line 27: | ||
'''| [[Digoxin Immune Fab clinical pharmacology|Clinical Pharmacology]]''' | '''| [[Digoxin Immune Fab clinical pharmacology|Clinical Pharmacology]]''' | ||
'''| [[Digoxin Immune Fab nonclinical toxicology|Nonclinical Toxicology]]''' | '''| [[Digoxin Immune Fab nonclinical toxicology|Nonclinical Toxicology]]''' | ||
'''| [[Digoxin Immune Fab how supplied storage and handling|How Supplied/Storage and Handling]]''' | '''| [[Digoxin Immune Fab how supplied storage and handling|How Supplied/Storage and Handling]]''' | ||
'''| [[Digoxin Immune Fab patient counseling information|Patient Counseling Information]]''' | '''| [[Digoxin Immune Fab patient counseling information|Patient Counseling Information]]''' | ||
Revision as of 19:32, 27 February 2014
| Digoxin Immune Fab |
|---|
| DIGIFAB® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Patient Counseling Information |
| Labels and Packages |
| Clinical Trials on Digoxin Immune Fab |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
For patient information about Digoxin immune fab, click here.
Synonyms / Brand Names: DIGIFAB ® injection
Overview
Digoxin Immune Fab (Ovine) is the generic name for an antidote for overdose of digitalis.[1] It is made from immunoglobin fragments from sheep who have already been immunized with a digoxin derivative, digoxindicarboxymethoxylamine (DDMA). Its brand names include Digibind and DigiFab, with the former manufactured by GlaxoSmithKline and the latter manufactured by Protherics, Inc.
Category
Digitalis antidote.
FDA Package Insert
DIGIFAB®
Indications and Usage | Dosage and Administration | Contraindications | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
Mechanism of Action
DigiFab has an affinity for digoxin in the range of 109 to 1010 M-1, which is greater than the affinity of digoxin for its sodium pump receptor, the presumed receptor for its therapeutic and toxic effects. When administered to the intoxicated patient, DigiFab binds to molecules of digoxin reducing free digoxin levels, which results in a shift in the equilibrium away from binding to the receptors, thereby reducing cardio-toxic effects. Fab-digoxin complexes are then cleared by the kidney and reticuloendothelial system.
References
http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6832767f-db6b-4eea-b88b-bdfc905749e1